Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis.
Journal of Infectious Diseases.
Times cited: 7
Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1α administration: Studies using a novel interleukin-1 receptor antagonist.
Annals of Surgery.
Times cited: 21
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 705